Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology

V. Madan, H. Chinoy, C. E M Griffiths, R. G. Cooper

    Research output: Contribution to journalArticlepeer-review

    81 Downloads (Pure)

    Abstract

    In part 1 of this review, we examined the evidence behind the association between idiopathic inflammatory myopathies (IIM) and cancers. In view of the well-recognized association between cancer and myositis (hence the term cancer-associated myositis, or CAM), clinicians responsible for the management of patients with myositis must make important decisions regarding how intensively they undertake searches for malignancy. Clinicians must also decide how often such searches are repeated, and again how intensively, to optimize both cancer detection and treatment, and thus patient survival. As the risks of CAM are greatest in dermatomyositis, this is an issue of obvious importance to dermatologists. In this second of two reviews, we examine the role of autoantibodies as potential predictors of cancer risk in patients with IIM. © 2009 British Association of Dermatologists.
    Original languageEnglish
    Pages (from-to)561-565
    Number of pages4
    JournalClinical and Experimental Dermatology
    Volume34
    Issue number5
    DOIs
    Publication statusPublished - Jul 2009

    Keywords

    • IDIOPATHIC INFLAMMATORY MYOPATHIES
    • CLINICALLY AMYOPATHIC DERMATOMYOSITIS
    • SIGNAL RECOGNITION PARTICLE
    • POPULATION-BASED COHORT
    • RNA-BINDING PROTEIN
    • ANTI-MI-2 ANTIBODIES
    • JAPANESE PATIENTS
    • AUTOANTIBODIES
    • POLYMYOSITIS
    • MALIGNANCY

    Fingerprint

    Dive into the research topics of 'Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology'. Together they form a unique fingerprint.

    Cite this